Pyrimethamine (PYR)

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Erasmus Medical Center

Conditions

HIV (Human Immunodeficiency Virus)HIV -1 InfectionMalaria

Phase 1

Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...

CompletedNCT02511054

National Institute of Allergy and Infectious Diseases (NIAID)Malaria

Start: 2015-07-21End: 2017-06-01Updated: 2017-07-02

Combining Latency Reversing Agents to Address the HIV Reservoir

Not yet recruitingNCT07384624

Erasmus Medical CenterHIV -1 Infection, HIV (Human Immunodeficiency Virus)

Start: 2026-04-01End: 2028-07-01Target: 30Updated: 2026-02-03

Related Papers

Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity.

2021-06-3091 citations